Tata Memorial Hospital study shows Nimotuzumab with standard treatment improves 10-year head and neck cancer survival rate.
Tata Memorial Hospital in Mumbai found that adding Nimotuzumab to standard treatment for head and neck cancer significantly improved the 10-year overall survival rate. In a Phase III study of 536 patients, those receiving this drug in combination with concurrent radiotherapy and cisplatin had a 33.5% 10-year survival rate, compared to 22.5% for patients receiving only radiotherapy and cisplatin. The research indicates that Nimotuzumab is both effective and safe.
July 30, 2024
6 Articles